Savara (SVRA) EBITDA (2010 - 2026)
Savara's (SVRA) quarterly EBITDA came in at -$39.0 million in Q1 2026, down 37.12% year-on-year from -$62.0 million in Q1 2025, and down 16.67% on a QoQ basis from -$33.4 million in Q4 2025.
Savara (SVRA) EBITDA (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of EBITDA data on file, last reported at -$39.0 million in Q1 2026.
- On a quarterly basis, EBITDA fell 37.12% year-over-year to -$39.0 million in Q1 2026; TTM through Mar 2026 was -$134.1 million, a 22.86% decrease from a year earlier, with the FY2025 full-year figure at -$123.5 million, down 19.72% from the prior year.
- EBITDA for Q1 2026 stood at -$39.0 million, down from -$33.4 million in the prior quarter.
- Over the last five years, EBITDA for SVRA reached as high as -$8.0 million in Q1 2022 and fell as low as -$39.0 million in Q1 2026.
- Historically, EBITDA has averaged -$21.4 million across 5 years, with a median of -$22.5 million in 2024.
- Across the five-year window, EBITDA increased 22.74% in 2022 and slumped 89.76% in 2024, its largest moves.
- Year by year, EBITDA stood at -$10.9 million in 2022, then sank by 62.11% to -$17.6 million in 2023, then plunged by 76.82% to -$31.2 million in 2024, then fell by 7.2% to -$33.4 million in 2025, then fell by 16.67% to -$39.0 million in 2026.
- Per Business Quant data, the three most recent EBITDA figures were -$39.0 million in Q1 2026, -$33.4 million in Q4 2025, and -$30.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | -38.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.99 Mn |
| Dec 31, 2025 | -33.42 Mn |
| Sep 30, 2025 | -30.26 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -28.44 Mn |
| Dec 31, 2024 | -31.17 Mn |
| Sep 30, 2024 | -26.36 Mn |
| Jun 30, 2024 | -23.19 Mn |
| Mar 31, 2024 | -22.48 Mn |
| Dec 31, 2023 | -17.63 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -12.22 Mn |
| Mar 31, 2023 | -12.11 Mn |
| Dec 31, 2022 | -10.88 Mn |
| Sep 30, 2022 | -10.54 Mn |
| Jun 30, 2022 | -9.38 Mn |
| Mar 31, 2022 | -8.05 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -9.97 Mn |
| Jun 30, 2021 | -10.45 Mn |